APRE · Aprea Therapeutics, Inc. · Executive Compensation
Market Cap
$9.73M
Shares
12.59M
Volume · Oct 6
199.18K
Avg daily vol (3M)
269.04K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Christian S. Schade | President and Chief Executive Officer | $3,677,567 |
| Scott M. Coiante | Chief Financial Officer | $1,809,419 |
| Eyal C. Attar | Chief Medical Officer | $1,189,283 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Christian S. Schade | President and Chief Executive Officer | $593,280 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Richard Peters, M.D., Ph.D. | Chairperson of the Board | Appointed | 2023-08-24 |
| Jean-Pierre Bizzari | Class III director | Appointed | 2023-08-24 |
| Christian S. Schade | Board of Directors | Resigned | 2023-08-24 |
| Christian S. Schade | Chairperson of the Board | Resigned | 2023-08-24 |
| Gabriela Gruia, M.D. | Class II director | Appointed | 2023-05-08 |
| John Hamill | Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer | Appointed | 2023-01-30 |